Table 4. Therapeutic regimens used to treat patients with PIK3CA mutations.
| Regimen | Mechanism of action | Patients (Case number*) |
% | Reference |
|---|---|---|---|---|
| Temsirolimus | mTORC1 inhibitor | 5 (4, 10, 11, 15, 17) |
29 | NCT00877773 |
| Temsirolimus, bevacizumab | mTORC1 inhibitor, anti-VEGF monoclonal antibody | 2 (8, 13) |
12 | NCT00610493 |
| Temsirolimus, liposomal doxorubicin, bevacizumab | mTORC1 inhibitor, anti-VEGF monoclonal antibody, topo II alpha inhibitor | 8 (1, 3, 5, 12, 16, 18, 20, 21) |
47 | NCT00761644 |
| Temsirolimus, topotecan, bortezomib | mTORC1 inhibitor, topoisomerase I inhibitor, proteasome inhibitor | 1 (25) |
6 | NCT00770731 |
| XL147, carboplatin, paclitaxel | PI3K inhibtor, alkylating agent, microtubule stabilizing agent | 1 (6) |
6 | Wheler et al.11 |
*
Case numbers are depicted in Table 2
NCT: clinicaltrials.gov identifier